here's what Cantor is saying below
We will have a very clear development pathway on Femprox within the next 5 weeks, in terms of Cantor, at least they initiated coverage, this is a starting point, the market has been waiting a year for that pathway on Femprox,
personally I think it will be significant, with improvements over the last trial 9 years ago, and coming events will force Cantor to upgrade their initiation, which will be sooner than later
I totally disagree with Cantor's peak sales on Vitaros and royalties, just consider the size of partner deals and milestones so far,
FROM SEEKING ALPHA: Cantor initiation
"The story needs more time to develop," Cantor's Irina Rivkind says of
Apricus Biosciences (APRI +0.5%) which is initiated at Hold with a $2
price target.
Rivkind expects peak royalties of $35M for Vitaros.
As for Femprox, the analyst wants "to get comfortable with the
development pathway." Nevertheless, "positive data in the 2016 time
frame could make APRI significantly more attractive."
what about this Cantor:
total Milestones Agreed for Vitaros so far in Dollars
December 2010 - Bracco SpA - $7.3 M
January 2011 - Elis Pharma - $2.1 M
February 2011 - Neopharm Group - $4.35 M
January 2012 - Abbott Laboratories - $16 M
February 2012 - Sandoz - Novartis - $28 M
September 2012 - Takeda Pharma - $46.6 M
Total Deals Milstones = about - $104.35M
$5.9 M received so far - see previous post
so about $98.5M in milestones left to receive so far,
does not include the next global partner milestone on Vitaros, or royalties
again, The next partner will pay more since the drug is approved now.
Market Data 
Markets 
AI
